Perreault, S.; Chami, R.; Deyell, R.J.; El Demellawy, D.; Ellezam, B.; Jabado, N.; Morgenstern, D.A.; Narendran, A.; Sorensen, P.H.B.; Wasserman, J.D.;
et al. Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients. Curr. Oncol. 2021, 28, 346-366.
https://doi.org/10.3390/curroncol28010038
AMA Style
Perreault S, Chami R, Deyell RJ, El Demellawy D, Ellezam B, Jabado N, Morgenstern DA, Narendran A, Sorensen PHB, Wasserman JD,
et al. Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients. Current Oncology. 2021; 28(1):346-366.
https://doi.org/10.3390/curroncol28010038
Chicago/Turabian Style
Perreault, Sébastien, Rose Chami, Rebecca J. Deyell, Dina El Demellawy, Benjamin Ellezam, Nada Jabado, Daniel A. Morgenstern, Aru Narendran, Poul H. B. Sorensen, Jonathan D. Wasserman,
and et al. 2021. "Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients" Current Oncology 28, no. 1: 346-366.
https://doi.org/10.3390/curroncol28010038
APA Style
Perreault, S., Chami, R., Deyell, R. J., El Demellawy, D., Ellezam, B., Jabado, N., Morgenstern, D. A., Narendran, A., Sorensen, P. H. B., Wasserman, J. D., & Yip, S.
(2021). Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients. Current Oncology, 28(1), 346-366.
https://doi.org/10.3390/curroncol28010038